Technical Analysis for GHRS - GH Research PLC
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bullish Engulfing | Bullish | -2.00% | |
Pocket Pivot | Bullish Swing Setup | -2.00% | |
Oversold Stochastic | Weakness | -2.00% | |
Oversold Stochastic | Weakness | 2.53% | |
Narrow Range Bar | Range Contraction | -1.67% | |
Wide Bands | Range Expansion | -1.67% | |
Up 3 Days in a Row | Strength | -1.67% | |
Oversold Stochastic | Weakness | -1.67% | |
NR7 | Range Contraction | -0.84% | |
Narrow Range Bar | Range Contraction | -0.84% |
Alert | Time |
---|---|
Rose Above Previous Day's High | about 6 hours ago |
Rose Above 10 DMA | about 6 hours ago |
Up 3% | about 6 hours ago |
Down 1% | about 6 hours ago |
Up 2% | about 6 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/15/2024
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Psychoactive Drugs Entheogens Treatment Resistant Depression Psychiatric And Neurological Disorders N Dimethyltryptamine
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Psychoactive Drugs Entheogens Treatment Resistant Depression Psychiatric And Neurological Disorders N Dimethyltryptamine
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 14.99 |
52 Week Low | 5.05 |
Average Volume | 55,031 |
200-Day Moving Average | 9.10 |
50-Day Moving Average | 12.25 |
20-Day Moving Average | 12.25 |
10-Day Moving Average | 11.85 |
Average True Range | 0.81 |
RSI (14) | 45.65 |
ADX | 29.02 |
+DI | 11.57 |
-DI | 21.38 |
Chandelier Exit (Long, 3 ATRs) | 12.57 |
Chandelier Exit (Short, 3 ATRs) | 13.60 |
Upper Bollinger Bands | 13.86 |
Lower Bollinger Band | 10.64 |
Percent B (%b) | 0.34 |
BandWidth | 26.30 |
MACD Line | -0.22 |
MACD Signal Line | -0.15 |
MACD Histogram | -0.0777 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 12.71 | ||||
Resistance 3 (R3) | 12.71 | 12.39 | 12.55 | ||
Resistance 2 (R2) | 12.39 | 12.15 | 12.39 | 12.49 | |
Resistance 1 (R1) | 12.07 | 12.00 | 12.23 | 12.07 | 12.44 |
Pivot Point | 11.76 | 11.76 | 11.84 | 11.75 | 11.76 |
Support 1 (S1) | 11.43 | 11.51 | 11.60 | 11.43 | 11.06 |
Support 2 (S2) | 11.12 | 11.36 | 11.12 | 11.01 | |
Support 3 (S3) | 10.80 | 11.12 | 10.95 | ||
Support 4 (S4) | 10.79 |